New study warns that some treatments for diabetes could lead to kidney complications

WashingtonAccording to a new study, attempts to normalize blood pressure and cholesterol could have long-term adverse effects on the kidney health of adults with type 2 diabetes who are at high risk for cardiovascular disease.

The findings, which appeared in the Clinical Journal of the American Society of Nephrology (CJASN), will be presented at ASN's Kidney Week in 2018.

Type 2 diabetes significantly increases the risk of cardiovascular disease and chronic kidney disease. Therefore, it is particularly important to protect the heart and kidney health of patients with type 2 diabetes.

In these patients, aggressive control of blood glucose, blood pressure, and cholesterol resulted in contradictory short-term effects on kidney health.

To determine the long-term effects on the kidneys of these interventions, Amy K. Mottl, Timothy E. Craven and their colleagues reviewed information relating to more than 10,000 participants at ACCORDION, an extension phase of the program. ACCORD trial, a multifactorial intervention study in people with type 2 diabetes present a high risk of cardiovascular disease.

The team found that intensive blood glucose control for normal mean blood glucose (hemoglobin target A1c <6%) reduced the risk of macroalbuminuria (a large amount of protein excreted in the urine) on a mean follow-up of blood glucose levels. 7.7 years. had no impact on more significant renal outcomes such as doubling serum creatinine (a marker of worsening renal function) or the need for dialysis or transplantation.

Intensive control of blood pressure or the use of fenofibrate to lower cholesterol increased the risk of doubling serum creatinine, but did not increase the need for dialysis or transplantation.

"These findings, along with those from the first study, which showed no benefit from interventions on heart attacks and strokes, provide evidence against aggressive targets for blood glucose, blood pressure and blood pressure. fenfibrate use in adults with type 2 diabetes at high risk of cardiovascular events, "said the researcher and Dr. Mottl.

…